TP0463518

Cat. No.:	HY-112144			
CAS No.:	1558021-37-6			
Molecular Formula:	C ₂₀ H ₁₈ ClN ₃ O ₆			
Molecular Weight:	431.83			
Target:	HIF/HIF Prolyl-Hydroxylase			
Pathway:	Metabolic Enzyme/Protease			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY


In Vitro	DMSO : ≥ 125 mg/mL (289.47 mM) * "≥" means soluble, but saturation unknown.						
1 0		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.3157 mL	11.5786 mL	23.1573 mL		
	Stock Solutions	5 mM	0.4631 mL	2.3157 mL	4.6315 mL		
	10 mM	0.2316 mL	1.1579 mL	2.3157 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution						

Description	TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with a K _i value of 5.3 nM for human
	PHD2. TP0463518 also inhibits human PHD1/PHD3 with IC $_{50}$ s of 18 and 63 nM as well as monkey PHD2 with an IC $_{50}$ value of
	22 nM ^[1] .

REFERENCES

Product Data Sheet

HO CI





[1]. Kato S, et al. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation. Eur J Pharmacol. 2018 Nov 5;838:138-144.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA